肾移植与血液透析患者COVID-19相关死亡率比较:前瞻性登记研究
该研究基于欧洲肾脏协会COVID-19数据库,比较1670例肾移植受者(496例)与血液透析患者(1174例)的28天死亡率。未调整时肾移植受者死亡风险较低(HR 0.67),但全调整后风险显著增高(HR 1.78),移植后第一年风险尤其突出。提示肾移植受者需针对性感染防控策略。
要点
- 未调整分析中肾移植受者28天死亡风险低于血液透析患者(HR 0.67)。
- 全调整后肾移植受者死亡风险为血液透析患者的1.78倍(HR 1.78)。
- 移植后第一年内COVID-19死亡风险显著增高。
核心结论
- 肾移植受者较血液透析患者有更高的COVID-19重症风险,需特定感染缓解策略。
研究设计与样本
- 采用Cox回归模型调整年龄、性别、衰弱和合并症,评估28天死亡风险。
主要发现
- 肾移植受者28天死亡率为16.9%,血液透析患者为23.9%。
- 未调整28天死亡风险肾移植受者较血液透析患者低33%(HR 0.67,95%CI 0.52-0.85)。
- 全调整模型肾移植受者28天死亡风险较血液透析患者高78%(HR 1.78,95%CI 1.22-2.61)。
- 因症状检测亚组全调整模型HR为2.00(95%CI 1.31-3.06)。
- 移植后第一年风险显著增加,其他终点(住院、ICU入住、>28天死亡)结果类似。
临床怎么用
- 肾移植受者应被视为COVID-19重症高危人群,需强化感染防控措施。
- 临床决策中需考虑移植后时间,尤其是第一年内的风险增高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coronavirus disease 2019 (COVID-19) has exposed haemodialysis (HD) patients and kidney transplant (KT) recipients to an unprecedented life-threatening infectious disease, raising concerns about kidney replacement therapy (KRT) strategy during the pandemic. This study investigated the association of the type of KRT with COVID-19 severity, adjusting for differences in individual characteristics. METHODS: Data on KT recipients and HD patients diagnosed with COVID-19 between 1 February 2020 and 1 December 2020 were retrieved from the European Renal Association COVID-19 Database. Cox regression models adjusted for age, sex, frailty and comorbidities were used to estimate hazard ratios (HRs) for 28-day mortality risk in all patients and in the subsets that were tested because of symptoms. RESULTS: A total of 1670 patients (496 functional KT and 1174 HD) were included; 16.9% of KT and 23.9% of HD patients died within 28 days of presentation. The unadjusted 28-day mortality risk was 33% lower in KT recipients compared with HD patients {HR 0.67 [95% confidence interval (CI) 0.52-0.85]}. In a fully adjusted model, the risk was 78% higher in KT recipients [HR 1.78 (95% CI 1.22-2.61)] compared with HD patients. This association was similar in patients tested because of symptoms [fully adjusted model HR 2.00 (95% CI 1.31-3.06)]. This risk was dramatically increased during the first post-transplant year. Results were similar for other endpoints (e.g. hospitalization, intensive care unit admission and mortality >28 days) and across subgroups. CONCLUSIONS: KT recipients had a greater risk of a more severe course of COVID-19 compared with HD patients, therefore they require specific infection mitigation strategies.
引用
- Goffin E, Candellier A, Vart P, et al. COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study. Nephrol Dial Transplant. 2021. PMID: 34132811. doi:10.1093/ndt/gfab200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。